| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7 (1), 1-11, 2019 | 131 | 2019 |
| The psychophysiology primer: a guide to methods and a broad review with a focus on human-computer interaction BU Cowley, M Filetti, K Lukander, J Torniainen, A Helenius, L Ahonen, ... Foundations and Trends in Human-Computer Interaction, 2016 | 88 | 2016 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: A real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327, 2019 | 65 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 56 | 2019 |
| Subliminal Salience Search Illustrated: EEG Identity and Deception Detection on the Fringe of Awareness H Bowman, M Filetti, D Janssen, L Su, A Alsufyani, B Wyble PLOS One 8 (1), e54258, 2013 | 46 | 2013 |
| Countering countermeasures: detecting identity lies by detecting conscious breakthrough H Bowman, M Filetti, A Alsufyani, D Janssen, L Su PloS one 9 (3), e90595, 2014 | 35 | 2014 |
| The cost of space independence in P300-BCI spellers S Chennu, A Alsufyani, M Filetti, AM Owen, H Bowman Journal of neuroengineering and rehabilitation 10 (1), 1-13, 2013 | 30 | 2013 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 29 | 2020 |
| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 26 | 2020 |
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in NSCLCs C Capalbo, G Scafetta, M Filetti, P Marchetti, A Bartolazzi International journal of molecular sciences 20 (7), 1607, 2019 | 25 | 2019 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 23 | 2020 |
| Immune-related adverse events of Pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical Lung Cancer 21 (6), 498-508. e2, 2020 | 22 | 2020 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 22 | 2020 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 20 | 2020 |
| Attention is more than prediction precision [Commentary on target article] H Bowman, M Filetti, B Wyble, C Olivers Behavioral and Brain Sciences 36 (3), 206-208, 2013 | 20 | 2013 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 16 | 2020 |
| Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: case report and literature review R Falcone, M Roberto, M Filetti, E Anselmi, P Marchetti Medicine 97 (3), 2018 | 12 | 2018 |
| Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes A Cortellini, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, ... Clinical and Translational Oncology, 1-8, 2019 | 11 | 2019 |
| Effective treatment of a platinum‑resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition C Capalbo, F Belardinilli, M Filetti, C Parisi, M Petroni, V Colicchia, ... Molecular and clinical oncology 9 (1), 30-34, 2018 | 11 | 2018 |
| Latency as a region contrast: Measuring ERP latency differences with dynamic time warping A Zoumpoulaki, A Alsufyani, M Filetti, M Brammer, H Bowman Psychophysiology 52 (12), 1559-1576, 2015 | 11 | 2015 |
